Price to Earnings (P/E)
since 2005
Paying user area
Try for free
Danaher Corp. pages available for free this week:
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Long-term (Investment) Activity Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Dividend Discount Model (DDM)
- Operating Profit Margin since 2005
- Price to Operating Profit (P/OP) since 2005
- Analysis of Revenues
- Analysis of Debt
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Danaher Corp. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Danaher Corp., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net earnings attributable to common stockholders1 (in millions) | ÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 20, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2008 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 15, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Danaher Corp. Annual Report.
The analysis of the financial data over the given periods reveals significant trends and fluctuations across key indicators such as share price, earnings per share (EPS), and price-to-earnings (P/E) ratio.
- Share Price
- The share price demonstrates an overall upward trend from 31.4 US$ in March 2006, reaching a peak of 262.39 US$ in February 2022. This increase represents substantial capital appreciation over the 16-year span. Notably, the price experienced a slight decline after the peak, falling to 250.11 US$ in February 2023, before stabilizing near 250.65 US$ in February 2024 and declining further to 207.95 US$ by February 2025. Despite the recent downtrend, the long-term growth in share price reflects positive market sentiment and potential investor confidence in the company's performance.
- Earnings per Share (EPS)
- EPS shows a general growth pattern with some volatility. Starting at 1.47 US$ in 2006, EPS increased steadily to 4.93 US$ by February 2021, with occasional fluctuations such as dips in 2009 (2.07 US$) and 2017-2018 period (3.68 and 3.57 US$ respectively). The peak EPS of 9.75 US$ was noted in February 2023, which significantly dropped to 6.41 US$ in 2024 and further to 5.46 US$ in 2025. This peak followed by decline may suggest operational challenges, changes in market conditions, or one-time effects impacting profitability.
- Price-to-Earnings (P/E) Ratio
- The P/E ratio started relatively moderate at 21.38 in 2006, fluctuated over the years, and exhibited a general increasing trend starting from 2015. It reached a historical high value of 44.49 in February 2021. The subsequent decrease to 29.94 in 2022 and further to 25.65 in 2023 indicates a market adjustment possibly due to the EPS growth outpacing the share price appreciation or broader market sentiment changes. However, the ratio surged again to values exceeding 38 in 2024 and 2025, signifying elevated market valuation relative to earnings, which may indicate investor expectations of future growth, or perceived risk and volatility.
Comparison to Competitors
Danaher Corp., P/E, long-term trends, comparison to competitors
| Danaher Corp. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 20, 2025 | ||||||||||||
| Feb 21, 2024 | ||||||||||||
| Feb 22, 2023 | ||||||||||||
| Feb 23, 2022 | ||||||||||||
| Feb 25, 2021 | ||||||||||||
| Feb 21, 2020 | ||||||||||||
| Feb 21, 2019 | ||||||||||||
| Feb 21, 2018 | ||||||||||||
| Feb 22, 2017 | ||||||||||||
| Feb 24, 2016 | ||||||||||||
| Feb 25, 2015 | ||||||||||||
| Feb 21, 2014 | ||||||||||||
| Feb 22, 2013 | ||||||||||||
| Feb 24, 2012 | ||||||||||||
| Feb 24, 2011 | ||||||||||||
| Feb 24, 2010 | ||||||||||||
| Feb 25, 2009 | ||||||||||||
| Feb 21, 2008 | ||||||||||||
| Mar 1, 2007 | ||||||||||||
| Mar 15, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Danaher Corp., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Danaher Corp. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 20, 2025 | ||
| Feb 21, 2024 | ||
| Feb 22, 2023 | ||
| Feb 23, 2022 | ||
| Feb 25, 2021 | ||
| Feb 21, 2020 | ||
| Feb 21, 2019 | ||
| Feb 21, 2018 | ||
| Feb 22, 2017 | ||
| Feb 24, 2016 | ||
| Feb 25, 2015 | ||
| Feb 21, 2014 | ||
| Feb 22, 2013 | ||
| Feb 24, 2012 | ||
| Feb 24, 2011 | ||
| Feb 24, 2010 | ||
| Feb 25, 2009 | ||
| Feb 21, 2008 | ||
| Mar 1, 2007 | ||
| Mar 15, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Danaher Corp., P/E, long-term trends, comparison to industry (health care)
| Danaher Corp. | Health Care | |
|---|---|---|
| Feb 20, 2025 | ||
| Feb 21, 2024 | ||
| Feb 22, 2023 | ||
| Feb 23, 2022 | ||
| Feb 25, 2021 | ||
| Feb 21, 2020 | ||
| Feb 21, 2019 | ||
| Feb 21, 2018 | ||
| Feb 22, 2017 | ||
| Feb 24, 2016 | ||
| Feb 25, 2015 | ||
| Feb 21, 2014 | ||
| Feb 22, 2013 | ||
| Feb 24, 2012 | ||
| Feb 24, 2011 | ||
| Feb 24, 2010 | ||
| Feb 25, 2009 | ||
| Feb 21, 2008 | ||
| Mar 1, 2007 | ||
| Mar 15, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).